OncoMatch/Clinical Trials/NCT06252298
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
Is NCT06252298 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SCTC21C for relapsed or refractory hematologic malignancies.
Treatment: SCTC21C — The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD38 overexpression (positive by immunohistochemistry or flow cytometry)
CD38+（confirmed by immunohistochemistry or flow cytometry）
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapies
Standard therapies failed or are unavailable or intolerant
Cannot have received: antineoplastic drug (except hormones)
other antineoplastic drug (except hormones) or radiotherapy within four weeks prior to the first dose of study drug
Cannot have received: radiotherapy
other antineoplastic drug (except hormones) or radiotherapy within four weeks prior to the first dose of study drug
Cannot have received: immunotherapy
immunotherapy or anti-CD38 monoclonal antibody within 6 months
Cannot have received: anti-CD38 monoclonal antibody
immunotherapy or anti-CD38 monoclonal antibody within 6 months
Lab requirements
Blood counts
platelet≥75x10^9 /l, absolute neutrophil counts ≥ 1.0x10^9 /l, hemoglobin ≥ 8.0 g/dl
Kidney function
basically normal kidney function
Liver function
basically normal liver function
Cardiac function
basically normal heart function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06252298 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antineoplastic drug (except hormones), radiotherapy, immunotherapy disqualifies patients from enrollment.
Does this trial require CD38?
Yes, CD38 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify